Lilly to us is going to emerge as the drug company of the decade.

Warner-Lambert is trying to maximize the price paid for the company. They think that they are entitled to a higher price, and this facilitates that.

Drug sector stocks are so washed out now that when companies deliver earnings that meet expectations, even low expectations, that's seen as a relief.

There's isolated incidents of companies (warning) because of patent expiration or pipeline problems or both, but they are very isolated.

That pair is in very elite company. I think we've seen more gifted inside-outside tandems, but you'd have to search long and hard to find a more polished pair.

The launch of the company will be much bigger than what Sprint would have done on its own, or Nextel,